Evotec and Novo Nordisk forge technology development partnership

Evotec SE

26/09/2024 07:07

Sept 26 (Reuters) - German drug and development company
Evotec  EVTG.DE  has entered into a technology development
partnership with Novo Nordisk  NOVOb.CO  to support clinical and
commercial manufacturing of stem cell-based therapies, the
company said on Thursday.
    Evotec will receive funding for technology development
activities in Germany and Italy, research and development
funding, an undisclosed upfront payment and possible milestone
and royalty payments, it added.
    In exchange, Novo Nordisk has an option to obtain exclusive
rights to utilise results of the collaboration.
    Shares in Evotec were up 6.9% at 0604 GMT in early Frankfurt
trade after the announcement.

 (Reporting by Isabel Demetz, Editing by Friederike Heine)
 ((Isabel.Demetz@thomsonreuters.com;))